{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:23:11Z","timestamp":1785252191870,"version":"3.55.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012639","name":"METAvivor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025561","name":"Glimmer of Hope Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025561","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["BC044784, BC132245, BC210533, BC211396"],"award-info":[{"award-number":["BC044784, BC132245, BC210533, BC211396"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Many cancers metastasize to the pleura, resulting in effusions that cause dyspnea and discomfort. Regardless of the tissue of origin, pleural malignancies are aggressive and uniformly fatal, with no treatment shown to prolong life. The pleural mesothelial monolayer is joined by tight junctions forming a contained bioreactor-like space, concentrating cytokines and chemokines secreted by the mesothelium, tumor, and infiltrating immune cells. This space represents a unique environment that profoundly influences tumor and immune cell behavior. Defining the pleural secretome is an important step in the rational development localized intrapleural immunotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We measured cytokine\/chemokine content of 252 malignant pleural effusion (MPE) samples across multiple cancers using a 40-analyte panel and Luminex multiplexing technology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven analytes were consistently present in concentrations \u2265 10.0 pM: CXCL10\/IP10 (geometric mean = 672.3 pM), CCL2\/MCP1 (562.9 pM), sIL-6R\u03b1 (403.1 pM), IL-6 (137.6 pM), CXCL1\/GRO (80.3 pM), TGF\u03b21 (76.8 pM), CCL22\/MDC (54.8 pM), CXCL8\/IL-8 (29.2 pM), CCL11\/Eotaxin (12.6 pM), IL-10 (11.3 pM), and G-CSF (11.0 pM). All are capable of mediating chemotaxis, promotion of epithelial to mesenchymal transition, or immunosuppression, and many of are reportedly downstream of a pro-inflammatory cytokine cascade mediated by cytokine IL-6 and its soluble receptor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The data indicate high concentrations of several cytokines and chemokines across epithelial cancers metastatic to the pleura and support the contention that the pleural environment is the major factor responsible for the clinical course of MPE across cancer types. A sIL-6R\u03b1 to IL-6 molar ratio of 2.7 ensures that virtually all epithelial, immune and vascular endothelial cells in the pleural environment are affected by IL-6 signaling. The central role likely played by IL-6 in the pathogenesis of MPE argues in favor of a therapeutic approach targeting the IL-6\/IL-6R axis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1404373","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:34:11Z","timestamp":1721795651000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["A common secretomic signature across epithelial cancers metastatic to the pleura supports IL-6 axis therapeutic targeting"],"prefix":"10.3389","volume":"15","author":[{"given":"Vera S.","family":"Donnenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Luketich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosko","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.","family":"Donnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-69538-1.00031-8","article-title":"Chapter 31 - thoracic metastatic disease","volume-title":"Oncologic Imaging : a Multidisciplinary Approach (Second Edition)","author":"Shroff","year":"2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/2193-1801-3-535","article-title":"Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors","volume":"3","author":"Weide","year":"2014","journal-title":"Springerplus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important prognostic factors for survival in patients with Malignant pleural effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC pulmonary Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.529","article-title":"Pleural effusion is a negative prognostic factor for immunotherapy in non small cell lung cancer (NSCLC): The PLUIE study","volume":"31","author":"Epaillard","year":"2020","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1038\/s41467-018-06867-x","article-title":"Mutational interactions define novel cancer subgroups","volume":"9","author":"Kuipers","year":"2018","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2019.04.012","article-title":"Metastasis organotropism: redefining the congenial soil","volume":"49","author":"Gao","year":"2019","journal-title":"Dev Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.846235","article-title":"Localized intra-cavitary therapy to drive systemic anti-tumor immunity","volume":"13","author":"Donnenberg","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1157697","DOI":"10.3389\/fimmu.2023.1157697","article-title":"A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells","volume":"14","author":"Donnenberg","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27290","article-title":"Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and Malignant mesothelioma: therapeutic implications","volume":"10","author":"Donnenberg","year":"2019","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.15406\/mojpb.2017.06.00200","article-title":"Correct use of percent coefficient of variation (%CV) formula for log-transformed data","volume":"6","author":"Canchola","year":"2017","journal-title":"MOJ Proteomics Bioinf"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.25.1_supplement.1036.3","article-title":"Barrier function of human pleura mesothelium is constituted by tight junctions","volume":"25","author":"Amasheh","year":"2011","journal-title":"FASEB J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199121040-00004","article-title":"Interleukins","volume":"21","author":"Bocci","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3041","article-title":"A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages","volume":"16","author":"Lu","year":"2014","journal-title":"Nat Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40425-019-0590-4","article-title":"Treatment of Malignant pleural effusions: the case for localized immunotherapy","volume":"7","author":"Donnenberg","year":"2019","journal-title":"J ImmunoTherapy Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/gb-2006-7-12-243","article-title":"The chemokine and chemokine receptor superfamilies and their molecular evolution","volume":"7","author":"Zlotnik","year":"2006","journal-title":"Genome Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2208176","DOI":"10.1155\/2022\/2208176","article-title":"Chemokine\/GPCR signaling-mediated EMT in cancer metastasis","volume":"2022","author":"Tian","year":"2022","journal-title":"J Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00592.x","article-title":"Chemokines produced by mesothelial cells: huGRO-alpha, IP-10, MCP-1 and RANTES","volume":"112","author":"Visser","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.61350","article-title":"TNF-\u03b1 augments CXCL10\/CXCR3 axis activity to induce Epithelial-Mesenchymal Transition in colon cancer cell","volume":"17","author":"Wang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.40535","article-title":"Wnt5a\/CaMKII\/ERK\/CCL2 axis is required for tumor-associated macrophages to promote colorectal cancer progression","volume":"16","author":"Liu","year":"2020","journal-title":"Int J Biol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302821","article-title":"CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2\/CCR2-dependent gene expression profile","volume":"192","author":"Sierra-Filardi","year":"2014","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1165\/ajrcmb.26.4.4613","article-title":"Production of eosinophilic chemokines by normal pleural mesothelial cells","volume":"26","author":"Katayama","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12964-019-0434-3","article-title":"CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition","volume":"17","author":"Lu","year":"2019","journal-title":"Cell Communication Signaling"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.10.4206-4209.1995","article-title":"Interleukin-8 production by human mesothelial cells after direct stimulation with staphylococci","volume":"63","author":"Visser","year":"1995","journal-title":"Infect Immun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14848","article-title":"IL-8 promotes cell migration through regulating EMT by activating the Wnt\/\u03b2-catenin pathway in ovarian cancer","volume":"24","author":"Wen","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.723846","article-title":"CXCL8 in tumor biology and its implications for clinical translation","volume":"9","author":"Xiong","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2024","article-title":"Role of eotaxin-1 signaling in ovarian cancer","volume":"15","author":"Levina","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v22.i2","article-title":"Regulation of macrophage-derived chemokine (MDC, CCL22) production","volume":"22","author":"Yamashita","year":"2002","journal-title":"Crit Rev Immunol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-36667-4_8","article-title":"CCL22 signaling in the tumor environment","volume-title":"Tumor Microenvironment: The Role of Chemokines \u2013 Part A","author":"R\u00f6hrle","year":"2020"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.03.040","article-title":"Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in Malignant pleural effusion","volume":"452","author":"Wang","year":"2019","journal-title":"Cancer Lett"},{"key":"B30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-030-36667-4_3","article-title":"CCL4 signaling in the tumor microenvironment","volume":"1231","author":"Mukaida","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000505099","article-title":"Interleukin-6: A masterplayer in the cytokine network","volume":"98","author":"Uciechowski","year":"2020","journal-title":"Oncology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00074.2003","article-title":"IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans","volume":"285","author":"Steensberg","year":"2003","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2009.5","article-title":"TGF-beta-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M413284200","article-title":"Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling","volume":"280","author":"Zhang","year":"2005","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611795","article-title":"Immunosuppressive mechanisms of regulatory B cells","volume":"12","author":"Catal\u00e1n","year":"2021","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 Signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2006.05.002","article-title":"The role of G-CSF in adaptive immunity","volume":"17","author":"Franzke","year":"2006","journal-title":"Cytokine Growth Factor Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v7i32","article-title":"TGF-\u03b2 induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201881","article-title":"IL-6 cooperates with G-CSF to induce protumor function of neutrophils in bone marrow by enhancing STAT3 activation","volume":"190","author":"Yan","year":"2013","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-119636","article-title":"IL6\/sIL6R complex contributes to emergency granulopoietic responses in G-CSF\u2013 and GM-CSF\u2013deficient mice","volume":"111","author":"Walker","year":"2008","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.150.11.4754","article-title":"Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation","volume":"150","author":"De Waal Malefyt","year":"1993","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.154.12.6291","article-title":"IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression","volume":"154","author":"Salazar-Onfray","year":"1995","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.9.5771","article-title":"IL-10: the master regulator of immunity to infection","volume":"180","author":"Couper","year":"2008","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13287-019-1359-x","article-title":"Nomenclature clarification: synovial fibroblasts and synovial mesenchymal stem cells","volume":"10","author":"Li","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67221","article-title":"IL-6 polymorphisms: a useful genetic tool for inflammation research","volume":"123","author":"Woo","year":"2013","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1101\/2023.02.07.23285472","article-title":"Altered IL-6 signalling and risk of tuberculosis disease: a meta-analysis and Mendelian randomisation study","author":"Hamilton","year":"2023","journal-title":"medRxiv"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.822091","article-title":"Effects of IL-6 polymorphisms on individual susceptibility to allergic diseases: A systematic review and meta-analysis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Genet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"17453","DOI":"10.1038\/s41598-020-74203-9","article-title":"The role of IL-6-174 G\/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis","volume":"10","author":"Ulhaq","year":"2020","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(96)90127-4","article-title":"Soluble interleukin-6 receptor levels in pleural effusions","volume":"90","author":"Yokoyama","year":"1996","journal-title":"Respir Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.d01-889.x","article-title":"IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases","volume":"107","author":"Dor\u00e9","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004174","article-title":"Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian randomisation study","volume":"20","author":"Hamilton","year":"2023","journal-title":"PLoS Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"100045","DOI":"10.1016\/j.soi.2024.100045","article-title":"Intra-pleural and intra-peritoneal tocilizumab therapy for managing Malignant pleural effusions and ascites: The Regional Immuno-Oncology Trial (RIOT)-2 study protocol","volume":"1","author":"Park","year":"2024","journal-title":"Surg Oncol Insight"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1404373\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:34:15Z","timestamp":1721795655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1404373\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2024.1404373"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1404373","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"article-number":"1404373"}}